Equities research analysts expect that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will report earnings per share of ($0.15) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.16). Achillion Pharmaceuticals reported earnings of ($0.03) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 400%. The business is scheduled to report its next quarterly earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.69) to ($0.60). For the next financial year, analysts forecast that the company will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.79) to ($0.55). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.04. During the same quarter in the prior year, the business earned ($0.15) earnings per share.

A number of research firms have recently weighed in on ACHN. ValuEngine cut shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Monday, September 11th. Robert W. Baird reaffirmed a “neutral” rating and set a $4.00 target price (down from $5.00) on shares of Achillion Pharmaceuticals in a report on Tuesday, September 12th. Ladenburg Thalmann Financial Services cut their target price on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a report on Tuesday, September 12th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 14th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. Achillion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $5.13.

In other news, major shareholder & Johnson Johnson sold 18,367,346 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 7.24% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. boosted its position in Achillion Pharmaceuticals by 3.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 800 shares during the period. SG Americas Securities LLC raised its stake in Achillion Pharmaceuticals by 18.6% during the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 4,144 shares in the last quarter. Legal & General Group Plc raised its stake in Achillion Pharmaceuticals by 53.8% during the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 15,000 shares in the last quarter. Voya Investment Management LLC raised its stake in Achillion Pharmaceuticals by 13.7% during the 2nd quarter. Voya Investment Management LLC now owns 55,819 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 6,730 shares in the last quarter. Finally, CIBC World Markets Inc. bought a new stake in Achillion Pharmaceuticals during the 2nd quarter valued at $280,000. Institutional investors own 76.92% of the company’s stock.

Shares of Achillion Pharmaceuticals (ACHN) traded down $0.08 on Friday, hitting $3.05. 1,475,520 shares of the stock traded hands, compared to its average volume of 2,980,000. The stock has a market capitalization of $408.38, a P/E ratio of -6.21 and a beta of 1.52. Achillion Pharmaceuticals has a 1-year low of $2.69 and a 1-year high of $5.66.

TRADEMARK VIOLATION NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.15 Per Share” was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.mareainformativa.com/achillion-pharmaceuticals-inc-achn-expected-to-announce-earnings-of-0-15-per-share-updated-updated-updated/124429/.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.